Cargando…
Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy
INTRODUCTION: Despite the recognized importance of atrophy in multiple sclerosis (MS), methods for its quantification have been mostly restricted to the research domain. Recently, a CE labelled and FDA approved MS-specific atrophy quantification method, MSmetrix, has become commercially available. H...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540882/ https://www.ncbi.nlm.nih.gov/pubmed/28794970 http://dx.doi.org/10.1016/j.nicl.2017.06.034 |
_version_ | 1783254698715774976 |
---|---|
author | Steenwijk, Martijn D. Amiri, Houshang Schoonheim, Menno M. de Sitter, Alexandra Barkhof, Frederik Pouwels, Petra J.W. Vrenken, Hugo |
author_facet | Steenwijk, Martijn D. Amiri, Houshang Schoonheim, Menno M. de Sitter, Alexandra Barkhof, Frederik Pouwels, Petra J.W. Vrenken, Hugo |
author_sort | Steenwijk, Martijn D. |
collection | PubMed |
description | INTRODUCTION: Despite the recognized importance of atrophy in multiple sclerosis (MS), methods for its quantification have been mostly restricted to the research domain. Recently, a CE labelled and FDA approved MS-specific atrophy quantification method, MSmetrix, has become commercially available. Here we perform a validation of MSmetrix against established methods in simulated and in vivo MRI data. METHODS: Whole-brain and gray matter (GM) volume were measured with the cross-sectional pipeline of MSmetrix and compared to the outcomes of FreeSurfer (cross-sectional pipeline), SIENAX and SPM. For this comparison we investigated 20 simulated brain images, as well as in vivo data from 100 MS patients and 20 matched healthy controls. In fifty of the MS patients a second time point was available. In this subgroup, we additionally analyzed the whole-brain and GM volume change using the longitudinal pipeline of MSmetrix and compared the results with those of FreeSurfer (longitudinal pipeline) and SIENA. RESULTS: In the simulated data, SIENAX displayed the smallest average deviation compared with the reference whole-brain volume (+ 19.56 ± 10.34 mL), followed by MSmetrix (− 38.15 ± 17.77 mL), SPM (− 42.99 ± 17.12 mL) and FreeSurfer (− 78.51 ± 12.68 mL). A similar pattern was seen in vivo. Among the cross-sectional methods, Deming regression analyses revealed proportional errors particularly in MSmetrix and SPM. The mean difference percentage brain volume change (PBVC) was lowest between longitudinal MSmetrix and SIENA (+ 0.16 ± 0.91%). A strong proportional error was present between longitudinal percentage gray matter volume change (PGVC) measures of MSmetrix and FreeSurfer (slope = 2.48). All longitudinal methods were sensitive to the MRI hardware upgrade that occurred during the time of the study. CONCLUSION: MSmetrix, FreeSurfer, FSL and SPM show differences in atrophy measurements, even at the whole-brain level, that are large compared to typical atrophy rates observed in MS. Especially striking are the proportional errors between methods. Cross-sectional MSmetrix behaved similarly to SPM, both in terms of mean volume difference as well as proportional error. Longitudinal MSmetrix behaved most similar to SIENA. Our results indicate that brain volume measurement and normalization from T1-weighted images remains an unsolved problem that requires much more attention. |
format | Online Article Text |
id | pubmed-5540882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-55408822017-08-09 Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy Steenwijk, Martijn D. Amiri, Houshang Schoonheim, Menno M. de Sitter, Alexandra Barkhof, Frederik Pouwels, Petra J.W. Vrenken, Hugo Neuroimage Clin Regular Article INTRODUCTION: Despite the recognized importance of atrophy in multiple sclerosis (MS), methods for its quantification have been mostly restricted to the research domain. Recently, a CE labelled and FDA approved MS-specific atrophy quantification method, MSmetrix, has become commercially available. Here we perform a validation of MSmetrix against established methods in simulated and in vivo MRI data. METHODS: Whole-brain and gray matter (GM) volume were measured with the cross-sectional pipeline of MSmetrix and compared to the outcomes of FreeSurfer (cross-sectional pipeline), SIENAX and SPM. For this comparison we investigated 20 simulated brain images, as well as in vivo data from 100 MS patients and 20 matched healthy controls. In fifty of the MS patients a second time point was available. In this subgroup, we additionally analyzed the whole-brain and GM volume change using the longitudinal pipeline of MSmetrix and compared the results with those of FreeSurfer (longitudinal pipeline) and SIENA. RESULTS: In the simulated data, SIENAX displayed the smallest average deviation compared with the reference whole-brain volume (+ 19.56 ± 10.34 mL), followed by MSmetrix (− 38.15 ± 17.77 mL), SPM (− 42.99 ± 17.12 mL) and FreeSurfer (− 78.51 ± 12.68 mL). A similar pattern was seen in vivo. Among the cross-sectional methods, Deming regression analyses revealed proportional errors particularly in MSmetrix and SPM. The mean difference percentage brain volume change (PBVC) was lowest between longitudinal MSmetrix and SIENA (+ 0.16 ± 0.91%). A strong proportional error was present between longitudinal percentage gray matter volume change (PGVC) measures of MSmetrix and FreeSurfer (slope = 2.48). All longitudinal methods were sensitive to the MRI hardware upgrade that occurred during the time of the study. CONCLUSION: MSmetrix, FreeSurfer, FSL and SPM show differences in atrophy measurements, even at the whole-brain level, that are large compared to typical atrophy rates observed in MS. Especially striking are the proportional errors between methods. Cross-sectional MSmetrix behaved similarly to SPM, both in terms of mean volume difference as well as proportional error. Longitudinal MSmetrix behaved most similar to SIENA. Our results indicate that brain volume measurement and normalization from T1-weighted images remains an unsolved problem that requires much more attention. Elsevier 2017-06-30 /pmc/articles/PMC5540882/ /pubmed/28794970 http://dx.doi.org/10.1016/j.nicl.2017.06.034 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Regular Article Steenwijk, Martijn D. Amiri, Houshang Schoonheim, Menno M. de Sitter, Alexandra Barkhof, Frederik Pouwels, Petra J.W. Vrenken, Hugo Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy |
title | Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy |
title_full | Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy |
title_fullStr | Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy |
title_full_unstemmed | Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy |
title_short | Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy |
title_sort | agreement of msmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540882/ https://www.ncbi.nlm.nih.gov/pubmed/28794970 http://dx.doi.org/10.1016/j.nicl.2017.06.034 |
work_keys_str_mv | AT steenwijkmartijnd agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy AT amirihoushang agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy AT schoonheimmennom agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy AT desitteralexandra agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy AT barkhoffrederik agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy AT pouwelspetrajw agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy AT vrenkenhugo agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy |